You are now searching through our whole database. To make more specific queries, you can use our menu or go directly to papers, companies, trials, or events.
This pre-print pre-registered meta-analysis (s=24) comparing psychedelic-assisted therapy (PAT) and open-label traditional antidepressants (tAD) for major depression found no significant difference in effectiveness between the two approaches, with both producing clinically meaningful improvements, challenging previous assumptions about PAT's superiority when accounting for the unblinding effect present in psychedelic trials.
This open-label follow-up study (n=10) of Veterans with severe treatment-resistant depression (TRD) found that a single dose of psilocybin (25mg) significantly reduced depression for up to 12 months, though effects began to wane after 6 months, with 40% maintaining response and 30% maintaining remission at the 12-month follow-up.
This secondary analysis of an RCT (n=15) investigates the acute effects of MDMA (100mg) on anterior pituitary function in healthy adults. It finds that MDMA significantly activates the hypothalamic-pituitary-adrenal (HPA) axis, increasing both ACTH and cortisol levels. No significant effects were observed on other anterior pituitary hormones, though prolactin showed a mild, non-significant increase.
This Delphi consensus study (n=89) involved psychedelic researchers, clinicians, and past trial participants across 17 countries to develop reporting standards for extra-pharmacological variables in psychedelic clinical trials. It resulted in the ReSPCT guidelines, a 30-item framework covering physical environment, session procedures, therapeutic protocol, and subjective experiences, aiming to standardise how “set and setting” are documented in future research.
Psymposium Madrid 2025 (2–4 Oct): experts gather at ICOMEM to discuss neuroscience, clinical data, and policy for psychedelic therapies.
Fuertedélica 2025 marks the fourth edition of our international conference, bringing together researchers, practitioners, and enthusiasts to explore the latest developments in psychedelic studies.
Psychedelic research in May 2025 shows ketamine saves healthcare costs, esketamine remains safe long-term, and these therapies work differently than expected.
This randomised, waitlist-controlled exploratory study (n=29) of psychedelic-naïve clergy delivered two supported psilocybin sessions (20mg/70kg followed a month later by 20-30mg/70kg). Six months after screening (and still evident 16 months later) the psilocybin group showed sustained improvements in religious practice, leadership effectiveness and overall well-being, with 96 % ranking at least one session among their five most spiritually significant life events and no serious adverse events despite 46 % describing the experience as among their five most challenging.
This cost-utility analysis, alongside a randomized controlled trial (n=174), compared subcutaneous ketamine (twice-weekly for 4 weeks) with midazolam in treatment-resistant depression. Including midazolam costs, ketamine raised QALYs (0.435 vs 0.352) and was dominant with an 89–91 % chance of costing < $50 000/QALY, but once these comparator costs were excluded ketamine was no longer cost-effective (ICER ≈ $108 500–$251 250/QALY, ≤ 5 % probability).
This case study (n=2) of an open-label pilot study (n=10) explores psilocybin-assisted psychotherapy for women with anorexia nervosa (AN or partial remission). Two participants experienced the therapeutic emergence of previously dissociated traumatic memories, leading to remission of AN symptoms and meaningful weight gain at 3-month follow-up.
Psychedelic Database
Find everything on psychedelics as medicine. This page allows you to search through our whole database, from research papers to news articles, and from clinical trials to academic articles.
Next to our databases, don’t forget to check out our reports. The reports bring together the separate pieces of information from our database entries into written reports.
